Viral Infections of the Reproductive System
Viral STIs are among the most common and persistent infections of the reproductive system. Unlike bacterial STIs, most viral infections cannot be cured, only managed. Two viruses dominate this topic: herpes simplex virus (HSV) and human papillomavirus (HPV). Understanding how they spread, cause disease, and evade the immune system is central to both treatment and prevention.
Transmission and Treatment of Genital Herpes
Transmission
Genital herpes is caused by herpes simplex virus (HSV), primarily type 2 (HSV-2), though HSV-1 (traditionally associated with oral cold sores) increasingly causes genital infections as well. The virus spreads through direct contact with infectious lesions or bodily fluids such as saliva and genital secretions.
A critical point for exams: HSV can be transmitted during asymptomatic shedding, meaning the virus is actively being released from skin or mucosal surfaces even when no visible sores are present. This is a major reason herpes spreads so effectively.
Symptoms
- Primary infection: Patients often experience flu-like symptoms (fever, headache, muscle aches) along with painful, fluid-filled blisters on the genitals, rectum, or mouth. These blisters rupture to form shallow ulcers that typically heal within 2–4 weeks.
- Recurrent infections: Outbreaks tend to be milder, with fewer and smaller lesions. Triggers include stress, illness, and menstruation, all of which can temporarily suppress immune function.
Treatment
There is no cure for genital herpes. The virus establishes latency in sensory nerve ganglia (specifically the sacral dorsal root ganglia for genital herpes), where it hides from the immune system and can reactivate periodically.
- Antiviral medications (acyclovir, valacyclovir, famciclovir) shorten outbreak duration and reduce severity. When taken daily as suppressive therapy, they also decrease viral shedding and lower the risk of transmitting the virus to partners.
- Supportive care includes OTC pain relief and keeping lesions clean and dry to prevent secondary bacterial infections.
HPV and Its Health Consequences
Human papillomavirus (HPV) is the most common sexually transmitted infection. Over 100 types have been identified, with roughly 40 infecting the genital area. HPV types are classified by their disease associations:
- Low-risk types (e.g., types 6 and 11) cause genital warts but are not associated with cancer.
- High-risk types (e.g., types 16 and 18) are oncogenic, meaning they can drive the development of cancer. Together, types 16 and 18 account for approximately 70% of cervical cancer cases.
Genital Warts
Low-risk HPV types produce small, flesh-colored, cauliflower-like growths on the genitals or anal area. These are generally benign but can cause discomfort or itching. Treatment options include:
- Topical medications (imiquimod, podofilox)
- Cryotherapy (freezing the warts)
- Surgical removal
Cervical Cancer
Persistent infection with high-risk HPV types can cause precancerous changes in cervical epithelial cells that, if left undetected, progress to cervical cancer. The mechanism involves two viral oncoproteins:
- E6 targets and degrades the tumor suppressor protein p53, which normally triggers apoptosis (programmed cell death) in cells with DNA damage. Without p53, damaged cells survive and accumulate mutations.
- E7 inactivates the retinoblastoma protein (pRb), which normally acts as a brake on cell cycle progression. With pRb disabled, cells divide uncontrollably.
Together, E6 and E7 remove two major checkpoints on cell growth, allowing mutations to pile up and eventually leading to malignancy.
Screening and treatment:
- Regular Pap smears and HPV DNA testing detect precancerous changes early, when treatment is most effective.
- Treatment depends on the stage and may include conization (removal of a cone-shaped section of the cervix), hysterectomy, radiation therapy, or chemotherapy.
Prevention of Viral STIs
Vaccination
- The HPV vaccine (Gardasil 9 is the current version in the U.S.) protects against nine HPV types, including the high-risk types 16 and 18 and the wart-causing types 6 and 11. It is recommended for both males and females starting at age 11–12, with catch-up vaccination available through age 26.
- No vaccine is currently available for HSV, though several candidates are in development.
Safe Sex Practices
- Consistent and correct condom use reduces transmission risk but does not eliminate it. Both HPV and HSV can spread through skin-to-skin contact in areas a condom doesn't cover.
- Limiting the number of sexual partners decreases overall exposure risk.
- Regular STI screening for all partners helps catch infections early, even asymptomatic ones.
- Mutual monogamy with an uninfected partner, or abstinence, eliminates the risk of sexual transmission.
Education and Awareness
Reducing the stigma around STIs is important because stigma discourages people from getting tested and treated. Open communication between partners about STI status supports informed decision-making and earlier intervention.
Viral Strategies and Host Defenses
Immune Evasion
Reproductive tract viruses have evolved specific strategies to persist in the host:
- HSV downregulates MHC class I molecules on the surface of infected cells, making it harder for cytotoxic T cells to recognize and destroy them. HSV also establishes latency in nerve ganglia, a site largely inaccessible to immune surveillance.
- HPV infects only the basal epithelial cells of the skin and mucosa, which are relatively shielded from immune detection. HPV also produces proteins that interfere with interferon signaling, dampening the innate immune response.
Vertical Transmission
Some viruses can pass from mother to child during pregnancy, childbirth, or breastfeeding. While HSV is the most relevant example for this unit (neonatal herpes can be severe or fatal if the mother has an active outbreak during delivery), other vertically transmitted viruses include HIV, hepatitis B, and Zika virus.
Mucosal Immunity
The reproductive tract relies on mucosal immunity as its first line of defense against viral infections. This includes:
- Physical barriers (epithelial lining, mucus)
- Secretory IgA antibodies that neutralize pathogens at mucosal surfaces
- Resident immune cells (macrophages, dendritic cells, T cells) that detect and respond to viral entry